Novel biological agent for treating drug resistant tuberculosis and preparation method thereof

Abstract

The invention belongs to the technical field of biological agents and discloses a novel biological agent for treating drug resistant tuberculosis and a preparation method thereof. The novel biologicalagent for treating drug resistant tuberculosis is a tuberculosis specific lymphocyte and is prepared by utilizing IL-1 alpha, IL-2, a CD3 monoclonal antibody and tuberculosis specific antigens (CFP10, ESAT6). Compared with the conventional tuberculosis treatment method, the novel biological agent disclosed by the invention is reported for the first time at home and abroad, and obvious curative effects are achieved when patients with pulmonary tuberculosis are treated by utilizing lymphocytes cultured in vitro. For patients subjected to cell therapy, the number of lymphocytes in peripheral blood is obviously increased, the sputum examination result is rapidly turned to be negative, pulmonary shadow is rapidly absorbed, the course of disease is shortened, the mental state is improved, and the appetite and weight are increased. The living quality of the patients in anti-tuberculosis therapy is obviously improved.

Description

technical field [0001] The invention belongs to the technical field of biological preparations, in particular to a novel biological preparation for treating drug-resistant tuberculosis and a preparation method thereof. Background technique [0002] Tuberculosis caused by Mycobacterium tuberculosis infection is one of the major public health problems worldwide. WHO pointed out in its 2016 global tuberculosis report that in 2015, the number of new tuberculosis cases in the world increased by 10% compared with 2014, reaching 10.4 million cases, resulting in about 1.4 million deaths; the crisis of drug-resistant tuberculosis detection and treatment continued, 580,000 Only 125,000 (20%) of drug-resistant TB patients received treatment; three countries, India, China and Russia, accounted for 45% of all drug-resistant cases. Therefore, my country is one of the countries with a high incidence of tuberculosis, and it is also a country with a high incidence of drug-resistant tubercul...

AI Technical Summary

Problems solved by technology

However, due to the long-term passage, the activity of BCG is reduced and the immune regulation is not effective after clinical use, which makes traditional immunotherapy and prevention gradually fall into a dilemma

The prevalence of multidrug-resistant tuberculosis has made the existing conventional chemotherapy methods weak

In recent years, with the increasing emphasis on tuberculosis, countries have invested a lot of money in the research of new anti-tuberculosis drugs and new vaccines, but little progress has been made and it is far from meeting clinical needs. Therefore, due to the characteristics of multidrug-resistant tuberculosis itself, The effect of combined application of chemically synthesized drugs is greatly reduced

[0004] In summary, the existing problems in the prior art are: low efficiency of chemically synthesized drugs for treating multidrug-resistant tuberculosis

The main reason is that multidrug-resistant Mycobacterium tuberculosis has developed resistance mutations to various existing anti-tuberculosis chemical drugs. Synthetic drugs make it harder to treat MDR-TB

Images